Cargando…

Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology

Olaparib, niraparib, rucaparib, and talazoparib are poly (ADP-ribose) polymerase (PARP) inhibitors approved for the treatment of ovarian, breast, pancreatic, and/or prostate cancer. Poly (ADP-ribose) polymerase inhibitors are potent inhibitors of the PARP enzymes with comparable half-maximal inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bruin, Maaike A. C., Sonke, Gabe S., Beijnen, Jos H., Huitema, Alwin D. R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9734231/ https://www.ncbi.nlm.nih.gov/pubmed/36219340 http://dx.doi.org/10.1007/s40262-022-01167-6

Ejemplares similares

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2015)

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing
por: Verheijen, Remy B., et al.
Publicado: (2017)

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
por: Verheijen, Remy B., et al.
Publicado: (2017)

Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial
por: Verheijen, Remy B., et al.
Publicado: (2017)

Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review
por: Verrest, Luka, et al.
Publicado: (2021)

Development of a population pharmacokinetic/pharmacodynamic model for various oral paclitaxel formulations co-administered with ritonavir and thrombospondin-1 based on data from early phase clinical studies
por: van Eijk, Maarten, et al.
Publicado: (2022)

Correction to: Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review
por: Verrest, Luka, et al.
Publicado: (2021)

In vivo visualization of PARP inhibitor pharmacodynamics
por: McDonald, Elizabeth S., et al.
Publicado: (2021)

Predicting Chemotherapy Distribution into Breast Milk for Breastfeeding Women Using a Population Pharmacokinetic Approach
por: Damoiseaux, David, et al.
Publicado: (2023)

Using Network Biology to Bridge Pharmacokinetics and Pharmacodynamics in Oncology
por: Kirouac, D C, et al.
Publicado: (2013)

Intracellular Pharmacokinetics of Pyrimidine Analogues used in Oncology and the Correlation with Drug Action
por: Derissen, Ellen J. B., et al.
Publicado: (2020)

Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer
por: Crombag, Marie-Rose B.S., et al.
Publicado: (2016)

Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses
por: Keizer, Ron J, et al.
Publicado: (2015)

Fixed Dosing of Monoclonal Antibodies in Oncology
por: Hendrikx, Jeroen J.M.A., et al.
Publicado: (2017)

Toxicological analysis of azide and cyanide for azide intoxications using gas chromatography
por: Bruin, Maaike A. C., et al.
Publicado: (2020)

Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism
por: Wang, Jinhai, et al.
Publicado: (2021)

Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy
por: van Hasselt, J. G. Coen, et al.
Publicado: (2014)

Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib
por: Boosman, René J., et al.
Publicado: (2022)

Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment
por: de Vries Schultink, A. H. M., et al.
Publicado: (2016)

Corrigendum to “Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy”
por: van Hasselt, J. G. Coen, et al.
Publicado: (2015)

Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review
por: van Bussel, Mark T. J., et al.
Publicado: (2019)

Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors
por: Shin, Jai Moo, et al.
Publicado: (2013)

Application of Pharmacokinetic and Pharmacodynamic Analysis to the Development of Liposomal Formulations for Oncology
por: Ait-Oudhia, Sihem, et al.
Publicado: (2014)

Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter]
por: Hendrikx, Jeroen J M A, et al.
Publicado: (2020)

Combining Isotopic Tracer Techniques to Increase Efficiency of Clinical Pharmacokinetic Trials in Oncology
por: Roosendaal, Jeroen, et al.
Publicado: (2020)

Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
por: Centanni, Maddalena, et al.
Publicado: (2019)

Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes
por: van Eijk, Maarten, et al.
Publicado: (2019)

Stable Isotopically Labeled Intravenous Microdose Pharmacokinetic Trials as a Tool to Assess Absolute Bioavailability: Feasibility and Paradigm to Apply for Protein Kinase Inhibitors in Oncology
por: Roosendaal, Jeroen, et al.
Publicado: (2020)

Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
por: van der Kleij, Maud B. A., et al.
Publicado: (2023)

A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer
por: Geenen, Jill J. J., et al.
Publicado: (2021)

Population pharmacokinetic–pharmacodynamic modelling in oncology: a tool for predicting clinical response
por: Bender, Brendan C, et al.
Publicado: (2015)

Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology
por: Mweempwa, Angela, et al.
Publicado: (2019)

Long-term platinum retention after treatment with cisplatin and oxaliplatin
por: Brouwers, Elke EM, et al.
Publicado: (2008)

Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose?
por: Embaby, Alaa, et al.
Publicado: (2022)

A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients
por: van Erp, Nielka P., et al.
Publicado: (2016)

A physiologically based pharmacokinetic model for [(68)Ga]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients
por: Siebinga, Hinke, et al.
Publicado: (2023)

Dose Optimization in Oncology Drug Development: The Emerging Role of Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics
por: Papachristos, Apostolos, et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis
por: Jacobs, Bart A.W., et al.
Publicado: (2019)

Quantification of anti-SARS-CoV-2 antibodies in human serum with LC-QTOF-MS
por: de Jong, Karen A.M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8dtmr1db1v15vf6mfc0tau81hk